Blue­bird is still look­ing for more fi­nanc­ing as it brings sick­le cell ther­a­py to mar­ket: #JPM24

SAN FRAN­CIS­CO — Af­ter strik­ing deals for as much as $225 mil­lion in fi­nanc­ing, blue­bird bio’s CEO said the com­pa­ny is still on the look­out for more, in­clud­ing from a fu­ture part­ner or from an­oth­er source.

“There’s a lot of be­lief that a gene ther­a­py can’t be prof­itable,” CEO An­drew Oben­shain said in an in­ter­view with End­points News. Oben­shain, of course, be­lieves that it can be, and that the com­pa­ny will prove that as it launch­es its new gene ther­a­py for sick­le cell dis­ease. But it may take sev­er­al quar­ters to make be­liev­ers out of the mar­ket or a part­ner.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER